ReviewCurrent hypertension reports2017
The Complement System and Preeclampsia.
Review in Current hypertension reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Systematic review of the complement components as potential biomarkers of pre-eclampsia: pitfalls and opportunities.Frontiers in immunology · 2024Pooled it
- Therapeutics Beyond Delivery: Repurposed Drugs and Biologic Pathways.Current hypertension reports · 2026Review
- The Role of Complement and CD4 T Cells in Preeclampsia and Offspring Neurodevelopment.Current opinion in physiology · 2026Article
- Shared Genetics of Hypertension and Preeclampsia Converges on Immune Regulation.medRxiv : the preprint server for health sciences · 2026Article
- Placental and maternal microbiome adaptations in a preeclamptic-like mouse model.Frontiers in microbiomes · 2026Article
- Article
- Impact of Malaria Infection on the Diagnostic Performance of Adipsin for Preeclampsia in Pregnancy: A Case-Control Study.Journal of pregnancy · 2026Article
- Immunometabolic Dysregulation in Preeclampsia: Emerging Roles of Inflammation, Insulin Resistance, Uric Acid, and the Gut Microbiome.Mediators of inflammation · 2026Review
- Nicotinamide Attenuates Complement and Coagulation Pathways and Resultant Renal Fibrosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- The Role of Angiogenetic Factors in Preeclampsia.International journal of molecular sciences · 2025Review
- Approach to the prevention of atypical hemolytic uremic syndrome recurrence using eculizumab in a pregnant kidney transplant recipient with complement factor H gene mutation: a case report and literature review.Journal of nephrology · 2025Review
- High-fat diet induces pre-eclampsia through dampening cell-autonomous C3 in trophoblasts.Communications biology · 2025Article
- Proteome-Based Maternal Plasma and Serum Biomarkers for Preeclampsia: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2025Review
- Exosomal-complement system activation in preeclampsia.The journal of obstetrics and gynaecology research · 2025Review
- Understanding rare genetic variants within the terminal pathway of complement system in preeclampsia.Genes and immunity · 2025Article
- Distinct TYRO3 and PROS1 expression levels contribute to preeclampsia pathogenesis.Histochemistry and cell biology · 2025Article
- Expression of Properdin, the positive regulator of the Complement Alternative Pathway, at the fetal-maternal interface in Preeclampsia.Frontiers in immunology · 2025Article
- The role of complement in normal pregnancy and preeclampsia.Frontiers in immunology · 2025Review
- Scoping Review of Microbiota Dysbiosis and Risk of Preeclampsia.American journal of reproductive immunology (New York, N.Y. : 1989) · 2024Article
- Different Proteomic Profiles Regarding Antihypertensive Therapy in Preeclampsia Pregnant.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
purpose of reviewPreeclampsia affects 3-4% of pregnancies with few treatment options to reduce maternal and fetal harm. Recent evidence that targeting the complement system may be an effective therapeutic strategy in prevention or treatment of preeclampsia will be reviewed. RECENT
findingsStudies in humans confirm the safety and efficacy of C5 blockade in complement-mediated disorders of pregnancy, including preeclampsia. Animal models mimic the placental abnormalities and/or the maternal symptoms which characterize preeclampsia. These models in mouse and rat have defined a role for complement and its regulators in placental dysfunction, hypertension, proteinuria, endothelial dysfunction, fetal growth restriction, and angiogenic imbalance, thus informing future human studies. Targeting excessive complement activation, particularly the terminal complement complex (C5b-9) and C5a may be an effective strategy to prolong pregnancy in women with preeclampsia. Continued research is needed to identify the initiator(s) of activation, the pathways involved, and the key component(s) in the pathophysiology to allow development of safe and effective therapeutics to target complement without compromising its role in homeostasis and host defense.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.